ERYTHROMYCIN capsule, delayed release pellets

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

erythromycin (UNII: 63937KV33D) (erythromycin - UNII:63937KV33D)

থেকে পাওয়া:

Mayne Pharma Inc.

INN (আন্তর্জাতিক নাম):

erythromycin

রচনা:

erythromycin 250 mg

প্রশাসন রুট:

ORAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi

পণ্য সারাংশ:

Each Erythromycin Delayed-Release Capsule, USP, 250 mg has an orange transparent body and orange opaque cap. The cap and body are imprinted with "Erymax" and "250 mg" in black ink. Each capsule contains 250 mg erythromycin as enteric-coated pellets. The pellets are colored white. The capsules are available as follows: NDC 68308-250-10 Bottle of 100 capsules Store at controlled room temperature 15° C to 30° C (59° F to 86° F).

অনুমোদন অবস্থা:

New Drug Application Authorized Generic

পণ্য বৈশিষ্ট্য

ERYTHROMYCIN- ERYTHROMYCIN CAPSULE, DELAYED RELEASE PELLETS
MAYNE PHARMA INC.
----------
ERYTHROMYCIN DELAYED-RELEASE CAPSULES, USP
FULL PRESCRIBING INFORMATION
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
erythromycin delayed-release capsules, USP and other antibacterial
drugs, erythromycin
delayed-release capsules, USP should be used only to treat or prevent
infections that
are proven or strongly suspected to be caused by bacteria.
DESCRIPTION
Erythromycin delayed-release capsules, USP capsules contain
enteric-coated pellets of
erythromycin base for oral administration. Each erythromycin
delayed-release capsules,
USP contains 250 mg of erythromycin base. Also contains: lactose NF,
povidone USP,
and other ingredients. The capsule shell contains gelatin NF, titanium
dioxide USP, FD&C
Yellow #6, D&C Yellow #10 and FD&C Red #3.
Erythromycin is produced by a strain of_ Saccharopolyspora erythraea
_(formerly
_Streptomyces erythraeus_) and belongs to the macrolide group of
antibiotics. It is basic
and readily forms salts with acids but it is the base which is
microbiologically active.
Erythromycin base is (3_R _*, 4_S _*, 5_S _*, 6_R _*, 7_R _*, 9_R _*,
11_R _*, 12_R _*, 13_S _*, 14_R _*)-4-
[(2,6-Dideoxy-3-_C_-methyl-
3-_O_-methyl-α-L-_ribo_-hexopyranosyl)oxy]-14-ethyl-7,12,13-
trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-
trideoxy-3-(dimethylamino)-β-D-_xyl_o-
hexopyranosyl]oxy]-oxacyclo-tetradecane-2,10-dione.
ERYTHROMYCIN
CLINICAL PHARMACOLOGY
Orally administered erythromycin base and its salts are readily
absorbed in the
microbiologically active form. Interindividual variations in the
absorption of erythromycin
are, however, observed, and some patients do not achieve acceptable
serum levels.
Erythromycin is largely bound to plasma proteins, and the freely
dissociating bound
fraction after administration of erythromycin base represents 90
percent of the total
erythromycin absorbed. After absorption, erythromycin diffuses readily
into most body
fluids. In the absence of